At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CMND Clearmind Medicine, Inc.
Trading 03-28 12:27:23 EDT
1.05
+0.00
0.00%
| High1.06 | Low1.05 | Vol7.50K |
| Open1.06 | D1 Closing1.05 | Amplitude1.16% |
| Mkt Cap5.39M | Tradable Cap4.44M | Total Shares5.13M |
| T/O7.93K | T/O Rate0.18% | Tradable Shares4.23M |
| P/B1.89 | ROE-125.61% | EPS-1.29 |
| 52wk High2.30 | 52wk Low0.9512 | P/E-0.81 |
| Dividend0.00 | Div.Yield0.00 | ROA-43.89% |
Psychedelic: Exclusive talk with biotech company Clearmind Medicine
TipRanks · 03-22
Clearmind Medicine Moves Closer to CMND-100 Trial After Alcohol Use Disorder Drug Candidate Arrives in US
MT Newswires Live · 03-21
Clearmind Medicine’s FDA-Approved Clinical Trial for Cmnd-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
THOMSON REUTERS · 03-21
Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
GlobeNewswire · 03-21
Clearmind Medicine Inc - Signs Loi With Polyrizon for Intranasal Formulation for Its Psychedelic-Based Treatment Applications
THOMSON REUTERS · 03-19
Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
GlobeNewswire · 03-19
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial
TipRanks · 03-14
BRIEF-Scisparc, Clearmind apply for patent in South Korea for its co-developed treatment to overcome cocaine addiction
Reuters · 03-10
Scisparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea
THOMSON REUTERS · 03-10
SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea
GlobeNewswire · 03-10
Scisparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico
THOMSON REUTERS · 02-04
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico
GlobeNewswire · 02-04
Clearmind announces publication of patent for binge behavior treatment
TIPRANKS · 02-04
Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico
THOMSON REUTERS · 02-04
Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico
GlobeNewswire · 02-04
Clearmind Medicine announces shareholders meeting results
TIPRANKS · 01-07
Press Release: Clearmind Medicine Announces Shareholders Meeting Results
Dow Jones · 01-07
Top Midday Gainers
MT Newswires Live · 01-06
Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?
Benzinga · 01-06
Sector Update: Health Care Stocks Edge Higher Premarket Monday
MT Newswires Live · 01-06
Introduction
Company Name.
Clearmind Medicine, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
2022-11-11
Main Business:
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App